PORTLAND, Ore., March 14, 2017 — Nobilis Therapeutics announced today that the patent that the company filed in June of 2017 has received a notice of allowance. The patent is titled “TREATMENT OF RHEUMATOID ARTHRITIS USING NOBLE GAS MIXTURES” and covers a wide range of noble gas uses in the treatment of rheumatologic diseases.
“This is a major accomplishment for us,” said Dr. Vlad Bogin, company’s CEO. “This patent is based on extensive proprietary data that we were able to collect and analyze through our collaboration with talented researchers from the former Soviet Union who have been experimenting with the use of subanesthetic doses of noble gases to treat a variety of clinical conditions. The source data that we have access to are rather incredible and have allowed us to truly dominate the intellectual property domain in our field of interest.”
“I am very excited to see how my research of medical applications of noble gases is being steadily advanced towards clinical practice. It is simply astounding that an inert gas can possess anti-inflammatory properties and shows reproducible reduction in the levels of several cytokines not only in the central nervous system but also systemically.” said Dr. Alexander Dobrovolsky, MD, PhD, company’s core expert.
About Nobilis Therapeutics, Inc.
Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using controlled device administration of inert gases that have an exceptional safety profile proven by decades of clinical use. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric and neurodegenerative diseases and leverages the experience of its international team that has successfully used this technology in the treatment of over 2000 patients for conditions ranging from panic attacks to substance abuse.
Vlad Bogin, MD, FACP
3042 NW Monte Vista Terrace
Portland, OR 97210
Tel: (971) 229-1679